Ilva D. Rupenthal

Comparison of ion-activated in situ gelling systems for ocular drug delivery. Part 1: physicochemical characterisation and in vitro release.

Comparison of ion-activated in situ gelling systems for ocular drug delivery. Part 2: Precorneal retention and in vivo pharmacodynamic study.

In vitro release characteristics and cellular uptake of poly(D,L-lactic-co-glycolic acid) nanoparticles for topical delivery of antisense oligodeoxynucleotides.

Ion-activated in situ gelling systems for antisense oligodeoxynucleotide delivery to the ocular surface.

Improved corneal wound healing through modulation of gap junction communication using connexin43-specific antisense oligodeoxynucleotides.

Synergistic effect of chemical penetration enhancer and iontophoresis on transappendageal transport of oligodeoxynucleotides.

Injectable implants for the sustained release of protein and peptide drugs.

Cytotoxicity and vitreous stability of chemically modified connexin43 mimetic peptides for the treatment of optic neuropathy.

Dendrimers for gene delivery--a potential approach for ocular therapy?

Implants for drug delivery to the posterior segment of the eye: a focus on stimuli-responsive and tunable release systems.

Sustained intravitreal delivery of connexin43 mimetic peptide by poly(D,L-lactide-co-glycolide) acid micro- and nanoparticles--Closing the gap in retinal ischaemia.

Neuroprotection in the treatment of glaucoma--A focus on connexin43 gap junction channel blockers.

Intravitreal injection of lipoamino acid-modified connexin43 mimetic peptide enhances neuroprotection after retinal ischemia.

Ocular delivery systems for topical application of anti-infective agents.

Connexin43 in retinal injury and disease.

Ex vivo and In vivo Evaluation of Chitosan Coated Nanostructured Lipid Carriers for Ocular Delivery of Acyclovir.

In vitro and ex vivo corneal penetration and absorption models.

Nanoparticle cross-linked collagen shields for sustained delivery of pilocarpine hydrochloride.

Modern approaches to the ocular delivery of cyclosporine A.

Ex vivo investigation of ocular tissue distribution following intravitreal administration of connexin43 mimetic peptide using the microdialysis technique and LC-MS/MS.

PLGA nanoparticles for intravitreal peptide delivery: statistical optimization, characterization and toxicity evaluation.

Ocular drug delivery-eye on innovation.

Hyaluronic Acid Coated Albumin Nanoparticles for Targeted Peptide Delivery to the Retina.

Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies.

Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases.

Tonabersat Prevents Inflammatory Damage in the Central Nervous System by Blocking Connexin43 Hemichannels.

Nanoparticle-loaded biodegradable light-responsive in situ forming injectable implants for effective peptide delivery to the posterior segment of the eye.

Ultrasound-mediated nanoparticle delivery across ex vivo bovine retina after intravitreal injection.

Phase transition of a microemulsion upon addition of cyclodextrin - applications in drug delivery.

Drug-device combination approaches for delivery to the eye.

Medicated ocular bandages and corneal health: potential excipients and active pharmaceutical ingredients.

Overcoming ocular drug delivery barriers through the use of physical forces.

The inflammasome pathway is amplified and perpetuated in an autocrine manner through connexin43 hemichannel mediated ATP release.

Immunohistochemical Characterization of Connexin43 Expression in a Mouse Model of Diabetic Retinopathy and in Human Donor Retinas.

Formulation Development and Evaluation of the Therapeutic Efficacy of Brinzolamide Containing Nanoemulsions.

Erratum to "Ultrasound-mediated nanoparticle delivery across ex vivo bovine retina after intravitreal injection" [Eur. J. Pharm. Biopharm. 119 (2017) 125-136].

Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs.

Preclinical development of MGO Manuka Honey microemulsion for blepharitis management.

Randomised masked trial of the clinical safety and tolerability of MGO Manuka Honey eye cream for the management of blepharitis.

Development of a novel stability indicating RP-HPLC method for quantification of Connexin43 mimetic peptide and determination of its degradation kinetics in biological fluids.

Effects of enzymatic degradation on dynamic mechanical properties of the vitreous and intravitreal nanoparticle mobility.

Micelle directed chemical polymerization of polypyrrole particles for the electrically triggered release of dexamethasone base and dexamethasone phosphate.

Hyaluronic acid coated albumin nanoparticles for targeted peptide delivery in the treatment of retinal ischaemia.

Drug delivery to the lens for the management of cataracts.

Sustained Connexin43 Mimetic Peptide Release From Loaded Nanoparticles Reduces Retinal and Choroidal Photodamage.

Intracellular oligonucleotide delivery using the cell penetrating peptide Xentry.

Intravitreal pro-inflammatory cytokines in non-obese diabetic mice: Modelling signs of diabetic retinopathy.

Evaluation of 2 ex vivo Bovine Cornea Storage Protocols for Drug Delivery Applications.

Connexin43 hemichannel block protects against the development of diabetic retinopathy signs in a mouse model of the disease.

Ultrasound-responsive nanobubbles for enhanced intravitreal drug migration: An ex vivo evaluation.

Connexin43 hemichannels: A potential drug target for the treatment of diabetic retinopathy.

Preclinical studies evaluating the effect of semifluorinated alkanes on ocular surface and tear fluid dynamics.

Ex vivo evaluation of the stability, safety and antibacterial efficacy of an extemporaneous povidone-iodine preparation for ophthalmic applications.

Depot formulations to sustain periocular drug delivery to the posterior eye segment.

Connexin43 hemichannel block protects against retinal pigment epithelial cell barrier breakdown.

Corrigendum to "Overcoming ocular drug delivery barriers through the use of physical forces" [Advanced Drug Delivery Reviews 126 (2018) 96-112].

Topical semifluorinated alkane-based azithromycin suspension for the management of ocular infections.

Ocular drugs and drug delivery systems - Current trends and future perspectives.

Targeting connexin hemichannels to control the inflammasome: the correlation between connexin43 and NLRP3 expression in chronic eye disease.

Connexin Hemichannel Block Using Orally Delivered Tonabersat Improves Outcomes in Animal Models of Retinal Disease.

Validation of hyaluronic acid-agar-based hydrogels as vitreous humor mimetics for in vitro drug and particle migration evaluations.

Relationship between rheological properties and transverse relaxation time (T2) of artificial and porcine vitreous humour.

Xentry-Gap19 inhibits Connexin43 hemichannel opening especially during hypoxic injury.

Incorporation of ion exchange functionalized-montmorillonite into solid lipid nanoparticles with low irritation enhances drug bioavailability for glaucoma treatment.

Ex vivo evaluation of the influence of pH on the ophthalmic safety, antibacterial efficacy and storage stability of povidone-iodine.

Connexin therapeutics: blocking connexin hemichannel pores is distinct from blocking pannexin channels or gap junctions.

Micro-interaction of mucin tear film interface with particles: The inconsistency of pharmacodynamics and precorneal retention of ion-exchange, functionalized, Mt-embedded nano- and microparticles.

The influence of hyperglycemia on the safety of ultrasound in retinal pigment epithelial cells.

Characterization of Zinc Oxide Nanoparticle Cross-Linked Collagen Hydrogels.

Connexin43 hemichannel block inhibits NLRP3 inflammasome activation in a human retinal explant model of diabetic retinopathy.

Tonabersat Inhibits Connexin43 Hemichannel Opening and Inflammasome Activation in an In Vitro Retinal Epithelial Cell Model of Diabetic Retinopathy.

Formulation Considerations for the Management of Dry Eye Disease.

Differential Action of Connexin Hemichannel and Pannexin Channel Therapeutics for Potential Treatment of Retinal Diseases.

Effect of therapeutic UVC on corneal DNA: Safety assessment for potential keratitis treatment.

Gelatine-based drug-eluting bandage contact lenses: Effect of PEGDA concentration and manufacturing technique.

Ocular Distribution of Papaverine Using Non-aqueous Vehicles.